drugset / Trial / NCT01595841
Sirolimus Use in Angioplasty for Vascular Access Extension
Phase 2
Completed
17 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Pfizer · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Dialysis patients presenting for angioplasty intervention for graft failure will be randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess the time from primary failure or angioplasty intervention to second or next angioplasty intervention or graft failure.
Timeline
- Start
- 2011-12
- Primary completion
- 2022-03
- Completion
- 2022-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 2 mg | Oral |